**China’s Life Sciences Venture Capital Sector Continues to Heat Up**
**Key Points**
* **China’s life sciences venture capital sector has been growing rapidly in recent years.**.
* **In 2021, Chinese life sciences companies raised a record $15 billion in venture capital funding.**.
* **This growth is being driven by a number of factors, including the increasing prevalence of chronic diseases in China, the government’s support for the life sciences industry, and the growing number of experienced life sciences entrepreneurs in the country.**.
* **The growth of China’s life sciences venture capital sector is expected to continue in the coming years, as the country continues to invest in its healthcare system and the life sciences industry becomes increasingly globalized.**
**Introduction**
China’s life sciences venture capital sector has been growing rapidly in recent years. In 2021, Chinese life sciences companies raised a record $15 billion in venture capital funding, according to data from Preqin. This represents a significant increase from the $8.2 billion raised in 2020.
This growth is being driven by a number of factors, including the increasing prevalence of chronic diseases in China, the government’s support for the life sciences industry, and the growing number of experienced life sciences entrepreneurs in the country.
**Increasing Prevalence of Chronic Diseases**
The increasing prevalence of chronic diseases in China is a major driver of growth in the life sciences venture capital sector. According to the World Health Organization, chronic diseases account for 80% of deaths in China.
This increase in chronic diseases is due to a number of factors, including the aging population, the rising prevalence of obesity and diabetes, and the increasing levels of air pollution.
**Government Support**
The Chinese government has been supportive of the life sciences industry for a number of years. In 2015, the government launched the .
